[Trial Data] phase 2 biopsy endpoints, and what "resolution" means
Posting this because I searched for it and got nothing useful. Setup: 15mg, week 49, sulphur burps present but not ruining anything. I changed exactly one variable — biopsy — and tracked it for 12 weeks. Result: a difference, but a small one, and well inside what I would call noise if someone else posted it. So I am…
glucagon co-agonism has a different safety story
[removed by moderator]
This is correct. Do not generalise from tirzepatide.
hepatic fat and survodutide are the story
glucagon injection is a different vector than GLP-1
Which trial arm?
Disagree but this is the good kind of wrong — it is specific enough to be checked.